Barinthus Biotherapeutics completes all-stock acquisition by Beacon Topco
What's the deal? Barinthus BiotherapeuticsDealroom has a profile for this one. Try Dealroom →, a NasdaqDealroom has a profile for this one. Try Dealroom →-listed biotech, completed its acquisition by Beacon TopcoDealroom has a profile for this one. Try Dealroom → on September 9, 2026. The deal was executed through a court-sanctioned scheme of arrangement, making Barinthus a wholly-owned subsidiary of Beacon Topco.
The terms: Shareholders received 0.111 shares of Beacon Topco common stock for each Barinthus ordinary share held. Each American Depositary Share (ADS) represented one ordinary share, so ADS holders received the same exchange ratio. Fractional entitlements were cashed out under the scheme terms.
Why now? The completion follows a merger agreement first announced on September 29, 2025, and amended on February 22, 2026. The all-stock structure closes a deal roughly a year in the making.
What changes? Barinthus asked Nasdaq to suspend trading of its ADSs before the opening of trading on September 9, 2026, and to file a Form 25 with the Securities and Exchange Commission to delist and deregister the securities. With no ADSs outstanding, the company intends to file a Form 15 to suspend its reporting obligations. The BRNS ticker will cease trading.
For shareholders: At the effective time, former shareholders lost all rights tied to their shares except the right to receive the merger consideration. Equity awards, including options and restricted share units, were converted into equivalent awards over Beacon Topco common stock.
The signal: Barinthus becomes another public biotech taken private through consolidation, exiting the Nasdaq via a stock swap rather than a cash payout. For investors, the outcome ties their return to the value of Beacon Topco stock at the fixed 0.111 ratio.
Read more: minichart.com.sg
Image credit: Generated with Gemini
